<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014062</url>
  </required_header>
  <id_info>
    <org_study_id>0553-17</org_study_id>
    <nct_id>NCT04014062</nct_id>
  </id_info>
  <brief_title>Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.</brief_title>
  <official_title>An Assessor-blind, Balanced, Randomized, Two-treatment, Two-period, Single-dose, Two-way, Crossover, Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects Under Fed Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intas Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lambda Therapeutic Research Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intas Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was an assessor-blind, balanced, randomized, two-treatment, two-period,
      single-dose, two-way crossover, comparative, pharmacokinetic (PK) and pharmacodynamic (PD)
      study of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; INTP5 and US-Neulasta) in
      healthy, adult, human subjects under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The study staff taking care of subject's safety and the laboratory personnel doing the sample analysis of pharmacokinetic, pharmacodynamic and immunogenicity data are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>Area under the serum concentration versus time curve from time zero to infinity. Where AUC[0-infinity]= AUC[0-t] + Ct/λz(lambda-z), Ct is the last measurable concentration and λz(lambda-z) is the terminal rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>Maximum measured absolute neutrophil count (ANC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Endpoint: Pegfilgrastim AUC[0-t]</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoint: Pegfilgrastim T[Max]</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoint: Pegfilgrastim λz(Lambda-z)</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoint: Pegfilgrastim R^2 Adjusted</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz.
R^2 is the coefficient of Determination and can range from 0 to 1,; with higher values indicating greater predictability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoint: Pegfilgrastim t[1/2]</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>The terminal half-life calculated using the formula 0.693/λz(lambda-z).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]</measure>
    <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
    <description>The residual area in percentage determined by the formula, [(AUC[0-infinity]-AUC]0-t])/AUC0-infinity] x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoint: T[Max] for Baseline Non-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoint: E[Max], Baseline-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>Maximum measured absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoint: AUEC[0-t], Baseline-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoint: T[Max], Baseline-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>First order rate constant associated with the terminal (log-linear) portion of the curve. This is estimated via linear regression of time vs. log concentration.
This parameter will be calculated by linear least squares regression analysis using at least last three or more non-zero values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoint: t[1/2] for Baseline-adjusted ANC</measure>
    <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
    <description>The terminal half-life will be calculated as 0.693/λz(lamda-z).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity: Presence of Anti-drug Antibodies</measure>
    <time_frame>0-71 Days</time_frame>
    <description>Evaluation of immunogenicity is carried out in a tiered fashion:
Screening assay to assess if samples were positive or negative for anti-PegG-CSF.
Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim.
Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples.
Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>INTP5 Period I Crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Neulasta Period I Crossover</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>INTP5</intervention_name>
    <description>INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.</description>
    <arm_group_label>INTP5 Period I Crossover</arm_group_label>
    <arm_group_label>US Neulasta Period I Crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>US Neulasta</intervention_name>
    <description>US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
    <arm_group_label>INTP5 Period I Crossover</arm_group_label>
    <arm_group_label>US Neulasta Period I Crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Normal, healthy adult human volunteers between 18 and 45 years of age (both inclusive)
             living in and around Ahmedabad city or western part of India.

          2. Having body weight ≥50 kg and body mass index (BMI) between 18.5 and 29.9 (both
             inclusive), calculated as weight in kg/height in meter^2.

          3. Not having any significant disease in medical history or clinically significant
             abnormal findings during screening, abdominal ultrasonography, medical history,
             clinical examination, laboratory evaluations, 12-lead ECG and chest X-ray
             (posterior-anterior view; within the last 6 months) recordings.

          4. Volunteer who is a Non-smoker

          5. Able to understand and comply with the study procedures, in the opinion of the
             investigator.

          6. Able to give voluntary written informed consent for participation in the trial.

          7. In case of female subjects:

               -  Surgically sterilized at least 6 months prior to study participation;- Or - If a
                  woman of childbearing potential is willing to use a suitable and effective double
                  barrier contraceptive method or intra uterine device during the study.

               -  Serum pregnancy test (for female subjects) must be negative.

        Exclusion Criteria:

          1. Known hypersensitivity to the study drug or its constituents and/or hypersensitivity
             to E. coli derived proteins, and/or previous exposure to the study drug.

          2. History or presence of any disease or condition which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.

          3. Known case of hereditary fructose intolerance.

          4. Subjects with latex allergies will be excluded as the needle cover on the single-use
             pre-filled syringe contains dry natural rubber (latex).

          5. Any clinically significant laboratory finding including ANC, platelet, RBC count or
             hemoglobin level at the time of screening.

          6. Prior exposure to any peptide colony stimulating or growth factor, including
             erythropoietin, filgrastim or Pegfilgrastim; Prior exposure to vaccines,
             immunoglobulin preparations, or immunomodulator's within the past 6 months prior to
             receiving the first dose; evidence of E. coli diarrhea or diseases within 3 months.

          7. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or
             NSAIDs induced urticaria.

          8. Subjects with a history of pulmonary infiltrate or pneumonia in the last 6 months.

          9. History of any hematologic disease including sickle cell disorders.

         10. Smokers, or who have smoked within last six months prior to start of the study.

         11. Ingestion or use of any prescribed medication at any time within 1 month prior to
             receiving first dose in Period-I.

         12. Receipt of over-the-counter medicines which have not yet cleared from the body (5
             half-lives must have passed for the medicine to be considered to have cleared from the
             body).

         13. A recent history of harmful use of alcohol, i.e. alcohol consumption of more than 14
             standard drinks per week for men and more than 7 standard drinks per week for women (A
             standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40%
             distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or
             alcoholic products within 72 hours prior to receiving study medicine in Period-I.

         14. Use of any recreational drugs or history of drug addiction or testing positive in
             pre-study drug scans.

         15. Donation of blood (1 unit or 350 mL) or equivalent amount of blood substitute. Receipt
             of an investigational medicinal product or participation in a drug research study
             within a period of 180 days prior to the first dose of study medication. Elimination
             half-life of the study drug should be taken into consideration for inclusion of the
             subject in the study.

         16. Positive result for human immunodeficiency virus (HIV I &amp;/or II) and/or hepatitis B
             and C tests.

         17. History or presence of cancer because of which anticipated life span is less than 5
             years as per the investigator's assessment.

         18. History or presence of psychiatric disorders.

         19. Presence of tattoo or scars or any type of skin lesions due to infection, burning,
             wound or inflammation at the proposed site of injection.

         20. An unusual diet, for whatever reason (e.g. low-sodium), for 4 weeks prior to receiving
             the study medicine in Period-I. In any such case, subject selection will be at the
             discretion of the Principal Investigator.

         21. Consumption of grape fruit or grape fruit products within 72 hours prior to receiving
             study drug in Period-I.

         22. A history of difficulty in donating blood.

         23. Females, pregnant or lactating, or planning to become pregnant during the course of
             the study or found positive in pregnancy test at screening.

         24. Any infections in the last 4 weeks before receiving study medication in Period-I.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anshul Attrey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinu Jose, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intas Pharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gota</state>
        <zip>Ahmedabad-382481</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <results_first_submitted>July 19, 2019</results_first_submitted>
  <results_first_submitted_qc>September 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Healthy Volunteers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT04014062/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT04014062/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 144 subjects were planned and enrolled. Of these 144, 2 subjects withdrew before dosing. Hence, 142 subjects started the study, were dosed, and were considered for the study analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>INTP5 Period I, US Neulasta Period II Crossover</title>
          <description>Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta.
INTP5: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
US Neulasta: US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
        </group>
        <group group_id="P2">
          <title>US Neulasta Period I, INTP5 Period II Crossover</title>
          <description>Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5.
INTP5: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
US Neulasta: US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period I: Dosing</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64">Period I: Dosing, includes a washout period of 42 days before starting Period II: Crossover Dosing</participants>
                <participants group_id="P2" count="65">Period I: Dosing, includes a washout period of 42 days before starting Period II: Crossover Dosing</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Medical Grounds</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period II: Crossover Dosing</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>INTP5 Period I, US Neulasta Period II Crossover</title>
          <description>Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta.
INTP5: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
US Neulasta: US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
        </group>
        <group group_id="B2">
          <title>US Neulasta Period I, INTP5 Period II Crossover</title>
          <description>Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5.
INTP5: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
US Neulasta: US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="5.74"/>
                    <measurement group_id="B2" value="32.5" spread="6.38"/>
                    <measurement group_id="B3" value="33.6" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159.1" spread="7.99"/>
                    <measurement group_id="B2" value="159.3" spread="9.00"/>
                    <measurement group_id="B3" value="159.2" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="7.42"/>
                    <measurement group_id="B2" value="61.6" spread="8.49"/>
                    <measurement group_id="B3" value="60.8" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.77" spread="2.788"/>
                    <measurement group_id="B2" value="24.32" spread="3.188"/>
                    <measurement group_id="B3" value="24.04" spread="2.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]</title>
        <description>Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]</title>
          <description>Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.269" spread="240.2247"/>
                    <measurement group_id="O2" value="425.578" spread="219.8054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]</title>
        <description>Area under the serum concentration versus time curve from time zero to infinity. Where AUC[0-infinity]= AUC[0-t] + Ct/λz(lambda-z), Ct is the last measurable concentration and λz(lambda-z) is the terminal rate constant.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimilar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]</title>
          <description>Area under the serum concentration versus time curve from time zero to infinity. Where AUC[0-infinity]= AUC[0-t] + Ct/λz(lambda-z), Ct is the last measurable concentration and λz(lambda-z) is the terminal rate constant.</description>
          <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21015.8632" spread="12985.3760"/>
                    <measurement group_id="O2" value="18327.4192" spread="11156.1580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC</title>
        <description>Maximum measured absolute neutrophil count (ANC).</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC</title>
          <description>Maximum measured absolute neutrophil count (ANC).</description>
          <units>x10^3 cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.82" spread="9.009"/>
                    <measurement group_id="O2" value="37.97" spread="9.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC</title>
        <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC</title>
          <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
          <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
          <units>x10^3 cells*h/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6638.12" spread="1404.376"/>
                    <measurement group_id="O2" value="6554.04" spread="1465.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoint: Pegfilgrastim AUC[0-t]</title>
        <description>Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta.
Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product.
Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoint: Pegfilgrastim AUC[0-t]</title>
          <description>Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.</description>
          <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21001.567" spread="12983.9811"/>
                    <measurement group_id="O2" value="18312.112" spread="11156.5248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoint: Pegfilgrastim T[Max]</title>
        <description>The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoint: Pegfilgrastim T[Max]</title>
          <description>The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.189" spread="6.8110"/>
                    <measurement group_id="O2" value="25.754" spread="7.6188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoint: Pegfilgrastim λz(Lambda-z)</title>
        <description>Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoint: Pegfilgrastim λz(Lambda-z)</title>
          <description>Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.</description>
          <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.0094"/>
                    <measurement group_id="O2" value="0.019" spread="0.0088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoint: Pegfilgrastim R^2 Adjusted</title>
        <description>Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz.
R^2 is the coefficient of Determination and can range from 0 to 1,; with higher values indicating greater predictability.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoint: Pegfilgrastim R^2 Adjusted</title>
          <description>Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz.
R^2 is the coefficient of Determination and can range from 0 to 1,; with higher values indicating greater predictability.</description>
          <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
          <units>Coefficient of Determination</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" spread="0.0543"/>
                    <measurement group_id="O2" value="0.967" spread="0.0344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoint: Pegfilgrastim t[1/2]</title>
        <description>The terminal half-life calculated using the formula 0.693/λz(lambda-z).</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoint: Pegfilgrastim t[1/2]</title>
          <description>The terminal half-life calculated using the formula 0.693/λz(lambda-z).</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.963" spread="18.5548"/>
                    <measurement group_id="O2" value="44.824" spread="29.3461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]</title>
        <description>The residual area in percentage determined by the formula, [(AUC[0-infinity]-AUC]0-t])/AUC0-infinity] x 100.</description>
        <time_frame>Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) &amp; 504 (D-22) hours post-dose.</time_frame>
        <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]</title>
          <description>The residual area in percentage determined by the formula, [(AUC[0-infinity]-AUC]0-t])/AUC0-infinity] x 100.</description>
          <population>3 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PK parameters</population>
          <units>percent of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="0.117"/>
                    <measurement group_id="O2" value="0.139" spread="0.1726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoint: T[Max] for Baseline Non-adjusted ANC</title>
        <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoint: T[Max] for Baseline Non-adjusted ANC</title>
          <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.231" spread="16.0553"/>
                    <measurement group_id="O2" value="63.734" spread="13.1649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoint: E[Max], Baseline-adjusted ANC</title>
        <description>Maximum measured absolute neutrophil count (ANC)</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoint: E[Max], Baseline-adjusted ANC</title>
          <description>Maximum measured absolute neutrophil count (ANC)</description>
          <units>x10^3 cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.66" spread="8.531"/>
                    <measurement group_id="O2" value="33.84" spread="8.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoint: AUEC[0-t], Baseline-adjusted ANC</title>
        <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoint: AUEC[0-t], Baseline-adjusted ANC</title>
          <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
          <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
          <units>x10^3cells*h/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4626.40" spread="1163.806"/>
                    <measurement group_id="O2" value="4565.80" spread="1278.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoint: T[Max], Baseline-adjusted ANC</title>
        <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoint: T[Max], Baseline-adjusted ANC</title>
          <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.231" spread="16.0553"/>
                    <measurement group_id="O2" value="63.734" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC</title>
        <description>First order rate constant associated with the terminal (log-linear) portion of the curve. This is estimated via linear regression of time vs. log concentration.
This parameter will be calculated by linear least squares regression analysis using at least last three or more non-zero values.</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC</title>
          <description>First order rate constant associated with the terminal (log-linear) portion of the curve. This is estimated via linear regression of time vs. log concentration.
This parameter will be calculated by linear least squares regression analysis using at least last three or more non-zero values.</description>
          <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.011"/>
                    <measurement group_id="O2" value="0.02" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoint: t[1/2] for Baseline-adjusted ANC</title>
        <description>The terminal half-life will be calculated as 0.693/λz(lamda-z).</description>
        <time_frame>Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.</time_frame>
        <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoint: t[1/2] for Baseline-adjusted ANC</title>
          <description>The terminal half-life will be calculated as 0.693/λz(lamda-z).</description>
          <population>5 subjects having three consecutive missing samples in the elimination phase were excluded from the statistical analysis of AUC0-t and other elimination phase dependent PD parameters.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.98" spread="34.973"/>
                    <measurement group_id="O2" value="56.27" spread="31.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunogenicity: Presence of Anti-drug Antibodies</title>
        <description>Evaluation of immunogenicity is carried out in a tiered fashion:
Screening assay to assess if samples were positive or negative for anti-PegG-CSF.
Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim.
Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples.
Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.</description>
        <time_frame>0-71 Days</time_frame>
        <population>Only a fraction of the population was tested for Immunogenicity. Only participants that displayed treatment related AEs with plausible immune-mediated pathology were analysed for immunogenicity. The data below represents the outcomes for the fraction of each arm that was tested.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Treatment</title>
            <description>Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle of US Neulasta and a six week wash out period, patients received a single dose of INTP5
INTP5: A proposed pegfilgrastim biosimilar to US Neulasta. US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Treatment</title>
            <description>Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
Period II: After the first treatment cycle of INTP5 and a six week wash out period, patients received a single dose of US Neulasta.
INTP5: A proposed pegfilgrastim biosimilar to US Neulasta. US Neulasta: FDA-approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Presence of Anti-drug Antibodies</title>
          <description>Evaluation of immunogenicity is carried out in a tiered fashion:
Screening assay to assess if samples were positive or negative for anti-PegG-CSF.
Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim.
Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples.
Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.</description>
          <population>Only a fraction of the population was tested for Immunogenicity. Only participants that displayed treatment related AEs with plausible immune-mediated pathology were analysed for immunogenicity. The data below represents the outcomes for the fraction of each arm that was tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period I</title>
              <category_list>
                <category>
                  <title>Negative for anti-drug-</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive for anti-PegG-CSF</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Tested for Immunogenicity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutralizing antibody</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II</title>
              <category_list>
                <category>
                  <title>Negative for anti-drug-</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive for anti-PegG-CSF</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Tested for Immunogenicity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutralizing antibody</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>79 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>INTP5 Treatment</title>
          <description>INTP5: A proposed pegfilgrastim biosimiar to US Neulasta. Outcomes Measures were grouped by treatment. This Group includes patients that received INTP5 in either Period I or Period II.
Given that this was a crossover design, AE totals for the entire study are reported comprehensively for Period I (71 Subjects) and Period II (65 Subjects) combined for the 136 subjects who received this treatment. Due to participant dropout between treatments, the number at risk for a given treatment is lower than the starting population for the study.</description>
        </group>
        <group group_id="E2">
          <title>US Neulasta Treatment</title>
          <description>US Neulasta: FDA approved pegfilgrastim innovator product. Outcomes Measures were grouped by treatment. This Group includes patients that received US Neulasta in either Period I or Period II.
Given that this was a crossover design, AE totals for the entire study are reported comprehensively for Period I (71 Subjects) and Period II (64 Subjects) combined for the 135 subjects who received this treatment. Due to participant dropout between treatments, the number at risk for a given treatment is lower than the starting population for the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Human chorionic gonadotropin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anshul Attrey, M.D. Principal Investigator</name_or_title>
      <organization>Lambda Therapeutic Research Ltd.</organization>
      <phone>+91-79-40202020</phone>
      <email>anshulattrey@lambda-cro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

